The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
Edited News | UNMAS
The deadly legacy of conflicts old and new from Gaza to Sudan and beyond continues to kill and maim civilians on a near-daily basis, mine action workers said on Wednesday, as they appealed for greater support for their lifesaving work in a context of deep funding cuts.
1
1
1
Edited News | WMO , UNICEF
Asia: Lives upended in cyclone disasters, ‘extreme’ rainfall on the rise - UN agencies
Across southeast Asia, record-breaking rains and flooding caused by back-to-back tropical storms have claimed hundreds of lives and brought devastation and displacement upon entire communities, UN agencies said on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
At the bi-weekly press briefing in the Geneva on Friday the UN Human Rights Office raised grave concerns about the recent constitutional amendments adopted in Pakistan.
1
1
1
Edited News | OHCHR , UNOG
At the bi-weekly press briefing in Geneva, UN Human Rights Spokesperson made the following comment on the most recent killings in the occupied West Bank yesterday.
1
1
1
Edited News | OHCHR , UNOG
At the bi-weekly press briefing in the Geneva on Friday the UN Human Rights Office raised concerns about the military-controlled election in Myanmar, which starts next month and will be conducted in an atmosphere rife with threats and violence putting the lives of civilians at risk.
2
1
2
Press Conferences , Edited News | UNAIDS
World AIDS Day 2025: Overcoming disruption, transforming the AIDS response
1
1
1
Edited News | UN WOMEN
Gaza women are ‘last line of protection’ for their families amid attacks, hunger and harsh winter – UN Women
Women in Gaza are ensuring their families’ survival “with nothing but courage and exhausted hands” while violence continues and essentials remain in short supply, the UN’s gender equality agency warned on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
Since the ceasefire began on 27 November 2024, Israeli military strikes in Lebanon have killed at least 127 civilians. Nearly a year later, these attacks continue to increase, causing civilian deaths and damage to civilian structures.
2
1
2
Press Conferences , Edited News | UNCTAD
A new report by UN Trade and Development (UNCTAD) finds that the prolonged military operation and long-standing restrictions have driven the economy of the Occupied Palestinian Territory into its most severe contraction on record, wiping out decades of development gains and deepening fiscal and social fragility.
1
1
1
Edited News | UNICEF , WHO , WFP
Ongoing attacks and airstrikes attributed to Israeli forces in Gaza continue to kill and maim people of all ages in the shattered enclave despite an agreed ceasefire, UN agencies said on Friday.
1
1
1
Edited News | UNICEF , OCHA
Gaza: After Security Council vote humanitarians urge aid scale-up as winter rains hit families hard
Following the UN Security Council’s Monday endorsement of a US peace plan for Gaza, UN humanitarians urged prioritizing aid access under the scheme as severe rains and flooding deepened Palestinian suffering.
1
1
1
Edited News | UNHCR , UNMAS , WHO
Just how many people are still trapped in the Sudanese city of El Fasher?
That’s the burning question for relatives of the many thousands of people believed to still be there, since paramilitary fighters overran the regional capital of North Darfur last month, after a 500-day siege.